글로벌 자가면역질환 치료 시장 – 2031년까지의 산업 동향 및 예측

자가면역질환 치료 시장 분석 및 규모

면역억제제는 자가면역 질환 치료의 초석이며, 시장의 중요한 부분을 구성합니다. 이러한 약물은 자가면역 질환에서 신체 조직을 표적으로 삼는 과활성 면역 반응을 감소시켜 작용합니다. 일반적으로 처방되는 면역억제제로는 코르티코스테로이드, 메토트렉세이트, 사이클로스포린이 있습니다. 자가면역 질환에 대한 자연 치료법에 대한 관심이 증가하고 있으며, 전통적인 약리학적 접근 방식을 보완하고 환자에게 상태를 관리하기 위한 대체 옵션을 제공합니다.

글로벌 자가면역질환 치료 시장 규모는 2023년에 65억 4천만 달러로 평가되었으며, 2031년까지 117억 5천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 7.6%입니다.

Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화       

Market Definition

Autoimmune disease treatment typically involves managing symptoms and suppressing the immune response that targets the body's tissues. This can be achieved through medications such as immunosuppressants or corticosteroids, along with lifestyle changes and therapies aimed at reducing inflammation and supporting overall health.

Autoimmune Disease Treatment Market Dynamics

Drivers                                                                                          

• Growing Advancements in Medical Research and Technology

Breakthroughs in understanding the complex mechanisms underlying autoimmune diseases, including genetic predispositions and immune system dysregulation, have led to the development of more targeted and effective treatments. Technologies such as high-throughput screening, genome sequencing, and computational modeling have accelerated drug discovery and personalized medicine approaches, offering tailored treatments for specific autoimmune conditions and patient populations. Innovations in biologics, immunotherapies, and drug delivery systems continue to expand treatment options and improve patient outcomes, driving market growth and addressing unmet medical needs in autoimmune disease management.

• Growing Aging Population

Immune systems become dysregulated in the aging population, which leads to increased susceptibility to autoimmune diseases. The prevalence of autoimmune conditions such as rheumatoid arthritis, lupus, and psoriasis tends to rise with age. Consequently, the growing geriatric demographic drives increased demand for effective autoimmune disease treatments, spurring research, development, and commercialization efforts in the market.

Opportunities

• Increasing Healthcare Expenditure

There is an increase in financial backing for the research, development, and commercialization of innovative therapies with the expansion of healthcare budgets. This translates to increased investment in autoimmune disease research, leading to the discovery of novel treatment modalities and advancements in existing therapies. Higher healthcare expenditure allows for improved access to specialized healthcare services and treatments for autoimmune diseases, particularly in developing regions. The rise in healthcare spending fosters innovation, enhances patient care, and accelerates market growth within the autoimmune disease treatment sector.

• Increasing Personalized Medicine

Personalized medicines tailor therapeutic approaches to individual patients based on genetic, molecular, and clinical factors. This approach enables more precise diagnosis, prognosis, and treatment selection, optimizing therapeutic outcomes while minimizing adverse effects. In the context of autoimmune diseases, personalized medicine allows for the identification of specific disease subtypes, biomarkers, and immune pathways, facilitating the development of targeted therapies. Personalized medicine improves treatment effectiveness, patient contentment, and overall market expansion by tackling the diversity of autoimmune diseases and the unique variations among patients that fosters innovation and investment in the sector.

Restraints/Challenges

• High Cost of Treatment

Many therapies, particularly biologics and targeted drugs, come with hefty price tags, creating financial barriers for patients, healthcare systems, and insurers. Affordability concerns often limit access to these treatments, particularly in regions with limited healthcare resources or inadequate insurance coverage. The cost burden may result in delayed or foregone treatment, leading to poorer health outcomes for affected individuals. The high cost of treatment contributes to healthcare disparities, exacerbating inequalities in access to care and treatment outcomes among different socioeconomic groups.

• Lack of Disease Awareness

Many autoimmune diseases present with nonspecific symptoms and can be challenging to diagnose, leading to underrecognition and underdiagnosis by both patients and healthcare providers. This lack of awareness contributes to delays in seeking medical attention, resulting in delayed treatment initiation and progression of the disease. Furthermore, limited disease awareness may hinder patient education efforts and delay access to appropriate healthcare services and treatments, ultimately impacting treatment outcomes and market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In June 2023, AstraZeneca forged an exclusive collaborated with Quell Therapeutics to advance engineered T-regulator (Treg) cell therapies, targeting Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). This collaboration aims to harness the potential of Treg cell therapies for offering curative treatments for these autoimmune conditions
• In January 2023, Penn Medicine researchers made strides in personalized treatment for myasthenia gravis (MG), a rare autoimmune condition, by exploring chimeric antigen receptor (CAR) T cell therapy, commonly used in cancer treatment. This innovative approach holds promise for addressing MG, representing a significant step forward in autoimmune disease therapy
• In May 2022, Nuvig Therapeutics, Inc. was established with the goal of developing immune-modulating therapeutics to manage autoimmune diseases while preserving normal immune function effectively. The company secured USD 47 million in Series A financing, reflecting investor confidence in its innovative approach to autoimmune disease treatment
• In June 2022, Roivant Sciences and Pfizer collaborated to create Priovant Therapeutics, which focuses on developing and commercializing novel therapies for autoimmune diseases with high morbidity and mortality rates. This collaboration underscores the commitment of both companies to addressing the unmet medical needs in the autoimmune disease treatment landscape
• In February 2022, Revolo Biotherapeutics received authorization from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to commence two Phase II trials of its autoimmune disease medication candidate "1805". This regulatory milestone signifies progress in the development of a potential treatment for autoimmune diseases, moving toward clinical evaluation

Autoimmune Disease Treatment Market Scope

The market is segmented on the basis of product type, application, distribution channel, disease, mechanism of action, diagnostic, treatment, and product. The growth amongst these segments will help you and analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• B Cell Inhibitors
• T Cell Inhibitors
• Tumor Necrosis Factor Inhibitors
• Interleukin Inhibitors
• Immunosuppressants,
• Beta Interferons
• Insulin
• Others

Application

• Graves Disease
• Rheumatoid Arthritis
• Hashimotos Thyroiditis
• Vitiligo
• Type 1 Diabetes
• Pernicious Anemia
• Others

Distribution Channel

• Hospitals and Clinics
• Diagnostic Centers
• Drug Stores
• Pharmacies
• Others

Disease

• Crohn's Disease
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Multiple Sclerosis
• Systemic Lupus Erythematosus
• Psoriasis
• Ankylosing Spondylitis

Mechanism of Action

• TNF Inhibitors
• IL Blockers
• COX Inhibitors
• Phosphodiesterase Type 4 Inhibitors

Diagnostic

• Autoantibody Tests
• Antinuclear Antibody Tests
• Urinalysis
• Comprehensive Metabolic Panel
• Erythrocyte Sedimentation Rate

Treatment

• Drugs
• Physical Therapy

Product

• Diagnostic Equipment
• Drugs
• Therapeutic and Monitoring Equipment

Autoimmune Disease Treatment Market Regional Analysis/Insights

The market is analyzed, and market size insights and trends are provided by product type, application, distribution channel, disease, mechanism of action, diagnostic, treatment, and product as referenced above.

The countries covered in the tissue contact probe ablators market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Brazil, and Argentina.

북미는 주로 의료비 증가와 자가면역 질환 치료에 집중된 연구 개발 노력으로 인해 시장을 지배할 것으로 예상됩니다. 또한 이 지역은 기술 혁신의 급증으로 인해 혜택을 받아 글로벌 시장에서의 지배력을 더욱 강화합니다. 이러한 요소들이 모여 북미의 강점에 기여하여 자가면역 질환 치료 및 관리 분야의 발전에서 선두에 서게 됩니다.

아시아 태평양 지역은 다양한 산업에 걸친 연구개발(R&D) 활동의 급증으로 인해 성장을 가속화할 것으로 예상됩니다. 혁신과 기술에 대한 자금 지원 증가와 같은 유리한 정부 이니셔티브가 이러한 모멘텀을 더욱 촉진하고 있습니다. 이러한 역동적인 환경은 혁신을 촉진하고, 투자를 유치하며, 공공 및 민간 부문 간의 협업을 촉진합니다. 결과적으로 아시아 태평양 지역은 기술 발전과 경제 확장의 핫스팟으로 부상하여 글로벌 환경에서 핵심 플레이어로 자리 매김하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 자가면역 질환 치료 시장 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• Autoimmune Inc (미국)
• 지멘스 헬스케어 프라이빗 리미티드(독일)
• 루핀(인도)
• Thermo Fisher Scientific Inc(미국)
• Beckman Coulter, Inc(미국)
• 추가이제약 주식회사(일본)
• GSK plc (영국)
• 바이오젠(미국)
• Bayer AG(독일)
• 제넨텍 주식회사(미국)
• 머크 샤프 앤 도메 코퍼레이션(미국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 아스트라제네카(영국)
• F. 호프만-라 로슈 유한회사(스위스)
• 파이저 주식회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• 존슨앤존슨서비스(주)(미국)
• 암젠 주식회사(미국)
• 애벗(미국)

SKU-12167